An informed guide to the pandemic, with the latest developments and expert advice about prevention and treatment. |
(Was this email forwarded to you? Sign up here.) |
|
By Jonathan Wolfe and Amelia Nierenberg |
|
The U.S. reaches universal eligibility |
The United States passed a significant milestone in its vaccine rollout: As of today, all adults in every state, Washington, D.C., and Puerto Rico are now eligible for a Covid-19 vaccine. |
The states had rushed to meet the April 19 deadline set by President Biden two weeks ago, and today the final states — Hawaii, Massachusetts, New Jersey, Oregon, Rhode Island and Vermont — expanded eligibility. |
After a slow start in December, the pace of vaccinations in the U.S. has picked up considerably in recent months. More than 131 million people, or half of all American adults, had received at least one shot as of Sunday, and about 84.3 million people had been fully vaccinated, a third of the adult population. At its current pace, the U.S. will vaccinate 70 percent of its population by mid-June, but experts are warning Americans not to let their guards down. The virus is resurgent and the U.S. is averaging more than 67,000 new cases a day over the past seven days, up from over 54,000 a month ago. |
The next phase of the rollout will bring its own challenges. Some scientists and health officials believe that making more people eligible will ultimately get more people vaccinated more swiftly. But others have said they are worried that some of the most vulnerable people, including those 65 and older, may have trouble competing for a shot. About a fifth of that group has not received even one shot. |
As the vaccine supply expands, the extent of vaccine skepticism in the country will also come into focus. To combat vaccine hesitancy, the Biden administration is making an intense push today, which officials have likened to a “get out the vote” effort that will roll out on social media and radio and television programs. |
Officials are particularly concerned about a rise in vaccine hesitancy as federal health officials pause the use of the Johnson & Johnson dose while regulators examine six cases of rare blood clots among recipients. A Centers for Disease Control and Prevention advisory panel is expected to meet on Friday and make recommendations about the vaccine’s use. |
The science behind Covid ‘blah’ |
A year in, and we are languishing. That’s the academic term for the collective fog we’ve endured for more than a year — trouble concentrating, trouble staying motivated, trouble getting excited about the future. |
Languishing isn’t burnout, which is more a lack of energy. It’s not depression, with its lack of hope. Instead, it’s a sense of stagnation, of emptiness, of just-getting-by, a malaise that might be the dominant emotion of 2021. |
Adam Grant, a professor of management and psychology at Wharton, suggested we think of languishing as a midpoint between flourishing and depression. |
“Flourishing is the peak of well-being: You have a strong sense of meaning, mastery and mattering to others. Depression is the valley of ill-being: You feel despondent, drained and worthless,” Grant writes. |
There’s still more research to do, but giving the emotion a name might give us a way to move forward, Grant argues. |
“It could give us a socially acceptable response to ‘How are you?’ |
Instead of saying ‘Great!' or ‘Fine,’ imagine if we answered, ‘Honestly, I’m languishing.’ It would be a refreshing foil for toxic positivity — that quintessentially American pressure to be upbeat at all times.” |
Vaccine rollout |
|
Thank you for your support. Want to share The New York Times? Friends and family can enjoy unlimited digital access to our journalism with this special offer. |
What else we’re following |
|
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.